v3.25.4

Segment Information (Tables)

6 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Schedule of Financial Information Operating Segment

The following table presents selected financial information with respect to the Company’s single operating segment and its significant segment expenses for the three and six months ended December 31, 2025 and 2024:

Schedule of Financial Information Operating Segment

C			1				2
		Three Months Ended December 31,
		2025				2024
Pre-clinical and clinical studies		$	928,288			$	455,039
Contract manufacturing			47,835				435,999
Consultants and other research and development			188,614				329,497
Compensation and related benefits			632,123				423,899
Professional and consultant fees			478,283				196,282
Stock-based compensation expense			198,530				564,333
Directors’ and officers’ insurance			113,518				122,983
Facilities, fees and other related costs			32,719				60,119
Interest expense			17,439				59,696
Interest income			(85,410	)			(7,067	)
Grant income			(552,576	)			(177,703	)
Other			34				(47	)
Net loss		$	(1,999,397	)		$	(2,463,030	)

C			168,420				651,465
		Six Months Ended December 31,
		2025				2024
Pre-clinical and clinical studies		$	1,335,200			$	1,288,900
Contract manufacturing			168,420				651,465
Consultants and other research and development			471,108				595,029
Compensation and related benefits			953,459				730,512
Professional and consultant fees			1,188,477				512,076
Stock-based compensation expense			436,174				851,253
Directors’ and officers’ insurance			223,847				240,141
Facilities, fees and other related costs			103,485				130,899
Interest expense			34,878				119,393
Interest income			(195,026	)			(33,073	)
Grant income			(562,401	)			(423,065	)
Other			130				236
Net loss		$	(4,157,751	)		$	(4,663,766	)

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration